Exosome-based immunotherapy as an innovative therapeutic approach in melanoma.
Cancer vaccine
Drug delivery
Drug resistance
Exosome therapy
Melanoma
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
07
08
2024
accepted:
22
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
The malignant form of melanoma is one of the deadliest human cancers that accounts for almost all of the skin tumor-related fatalities in its later stages. Achieving an exhaustive understanding of reliable cancer-specific markers and molecular pathways can provide numerous practical techniques and direct the way toward the development of rational curative medicines to increase the lifespan of patients. Immunotherapy has significantly enhanced the treatment of metastatic and late-stage melanoma, resulting in an incredible increase in positive responses to therapy. Despite the increasing occurrence of melanoma, the median survival rate for patients with advanced, inoperable terminal disease has increased from around six months to almost six years. The current knowledge of the tumor microenvironment (TME) and its interaction with the immune system has resulted in the swift growth of innovative immunotherapy treatments. Exosomes are small extracellular vesicles (EVs), ranging from 30 to 150 nm in size, that the majority of cells released them. Exosomes possess natural advantages such as high compatibility with living organisms and low potential for causing immune reactions, making them practical for delivering therapeutic agents like chemotherapy drugs, nucleic acids, and proteins. This review highlights recent advancements in using exosomes as an approach to providing medications for the treatment of melanoma.
Identifiants
pubmed: 39482766
doi: 10.1186/s12964-024-01906-1
pii: 10.1186/s12964-024-01906-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
527Informations de copyright
© 2024. The Author(s).
Références
Mkhobongo B, Chandran R, Abrahamse H. The role of melanoma cell-derived exosomes (MTEX) and photodynamic therapy (PDT) within a tumor microenvironment. Int J Mol Sci. 2021;22(18):9726.
pubmed: 34575889
doi: 10.3390/ijms22189726
Surman M, Stępień E, Przybyło M. Melanoma-derived extracellular vesicles: focus on their proteome. Proteomes. 2019;7(2):21.
pubmed: 31086060
doi: 10.3390/proteomes7020021
Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatology. 2022;158(5):495–503.
pubmed: 35353115
doi: 10.1001/jamadermatol.2022.0160
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Pérez-Fidalgo JA, et al. Melanoma of unknown primary: new perspectives for an old story. Crit Rev Oncol/Hematol. 2021;158:103208.
pubmed: 33383207
doi: 10.1016/j.critrevonc.2020.103208
Zbytek B, Carlson JA, Granese J, Ross J, Mihm M, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatology. 2008;3(5):569–85.
pubmed: 19649148
doi: 10.1586/17469872.3.5.569
Nguyen K, Hignett E, Khachemoune A. Current and emerging treatment options for metastatic melanoma: a focused review. Dermatol Online J. 2020;26(7).
He G, Li Y, Zeng Y, Zhang Y, Jiang Q, Zhang Q, et al. Advancements in melanoma immunotherapy: the emergence of Extracellular Vesicle vaccines. Cell Death Discovery. 2024;10(1):374.
pubmed: 39174509
doi: 10.1038/s41420-024-02150-9
Korn EL, Liu P-Y, Lee SJ, Chapman J-AW, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527–34.
pubmed: 18235113
doi: 10.1200/JCO.2007.12.7837
Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24(29):4738–45.
pubmed: 16966688
doi: 10.1200/JCO.2006.06.0483
Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatology. 2021;141(1):23–31.
doi: 10.1016/j.jid.2020.03.943
Xu Z, Zeng S, Gong Z, Yan Y. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer. 2020;19:1–16.
doi: 10.1186/s12943-020-01278-3
Sharma V, Mukhopadhyay CD. Exosome as drug delivery system: current advancements. Extracell Vesicle. 2024;3:100032.
doi: 10.1016/j.vesic.2023.100032
Mason R, Au L, Ingles Garces A, Larkin J. Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opin Pharmacother. 2019;20(9):1135–52.
pubmed: 31025594
doi: 10.1080/14656566.2019.1601700
Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: recent advances and future directions. Cancers. 2023;15(4):1106.
pubmed: 36831449
doi: 10.3390/cancers15041106
Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies. J Exp Med. 2009;206(8):1717–25.
pubmed: 19581407
doi: 10.1084/jem.20082492
Lang B, Peveling-Oberhag A, Faidt D, Hötker A, Weyer-Elberich V, Grabbe S, et al. Long-term survival with modern therapeutic agents against metastatic melanoma—vemurafenib and ipilimumab in a daily life setting. Med Oncol. 2018;35:1–12.
doi: 10.1007/s12032-018-1084-9
Drysdale E, Peng Y, Nguyen P, Baetz T, Hanna TP. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma. Melanoma Res. 2019;29(6):635–42.
pubmed: 30789386
doi: 10.1097/CMR.0000000000000582
Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580–7.
pubmed: 23087408
doi: 10.1158/1078-0432.CCR-12-1362
Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767–78.
pubmed: 27806234
doi: 10.1056/NEJMra1514296
Robert C, Ribas A, Schachter J, Arance A, Grob J-J, Mortier L, et al. Pembrolizumab versus Ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51.
pubmed: 31345627
doi: 10.1016/S1470-2045(19)30388-2
Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38(33):3937.
pubmed: 32997575
doi: 10.1200/JCO.20.00995
Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med. 2016;14(1):20.
pubmed: 26850630
doi: 10.1186/s12916-016-0571-0
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.
pubmed: 26014293
doi: 10.1200/JCO.2014.58.3377
Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:1–14.
doi: 10.1186/s12943-019-1091-2
Maruhashi T, Sugiura D, Okazaki I-m, Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8(2).
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34.
pubmed: 34986285
doi: 10.1056/NEJMoa2109970
Renato Filho S, Oliveira DA, Nisimoto MM, Marti LC. A review for Advanced Cutaneous Melanoma therapies and their mechanisms, from immunotherapies to Lysine Histone Methyl Transferase inhibitors. 2023.
Lopes J, Rodrigues CM, Gaspar MM, Reis CP. Melanoma Management: from epidemiology to treatment and latest advances. Cancers. 2022;14(19):4652.
pubmed: 36230575
doi: 10.3390/cancers14194652
Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p. V600E BRAFmutations. BMC Cancer. 2014;14(1):1–13.
doi: 10.1186/1471-2407-14-13
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.
pubmed: 22663011
doi: 10.1056/NEJMoa1203421
Ernst M, Giubellino A. The current state of treatment and future directions in cutaneous malignant melanoma. Biomedicines. 2022;10(4):822.
pubmed: 35453572
doi: 10.3390/biomedicines10040822
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51.
pubmed: 26037941
doi: 10.1016/S0140-6736(15)60898-4
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus Binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15.
pubmed: 29573941
doi: 10.1016/S1470-2045(18)30142-6
Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, et al. Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. Eur J Cancer. 2020;126:33–44.
pubmed: 31901705
doi: 10.1016/j.ejca.2019.11.016
Li C, Kuai L, Cui R, Miao X. Melanogenesis and the targeted therapy of Melanoma. Biomolecules. 2022;12(12):1874.
pubmed: 36551302
doi: 10.3390/biom12121874
Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15(9):954–65.
pubmed: 25037139
doi: 10.1016/S1470-2045(14)70301-8
Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. OncoTargets Therapy. 2018:7095–107.
Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, et al. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma. Front Immunol. 2019;10:453.
pubmed: 30941125
doi: 10.3389/fimmu.2019.00453
Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835–44.
pubmed: 32534646
doi: 10.1016/S0140-6736(20)30934-X
Rodríguez-Cerdeira C, Carnero Gregorio M, López-Barcenas A, Sánchez-Blanco E, Sánchez-Blanco B, Fabbrocini G et al. Advances in immunotherapy for melanoma: a comprehensive review. Mediators of inflammation. 2017;2017.
Payandeh Z, Yarahmadi M, Nariman-Saleh‐Fam Z, Tarhriz V, Islami M, Aghdam AM, et al. Immune therapy of melanoma: overview of therapeutic vaccines. J Cell Physiol. 2019;234(9):14612–21.
pubmed: 30706472
doi: 10.1002/jcp.28181
Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Experimental Hematol Oncol. 2022;11(1):1–22.
doi: 10.1186/s40164-022-00257-2
Gargett T, Abbas MN, Rolan P, Price JD, Gosling KM, Ferrante A, et al. Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. Cancer Immunol Immunother. 2018;67:1461–72.
pubmed: 30014244
doi: 10.1007/s00262-018-2207-z
Bulgarelli J, Tazzari M, Granato AM, Ridolfi L, Maiocchi S, De Rosa F et al. Dendritic cell vaccination in metastatic melanoma turns non-T cell inflamed into T-cell inflamed tumors. Front Immunol. 2019:2353.
Verma V, Kim Y, Lee M-C, Lee J-T, Cho S, Park I-K, et al. Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression. Oncotarget. 2016;7(26):39894.
pubmed: 27223090
doi: 10.18632/oncotarget.9529
Larocca C, Schlom J. Viral vector–based therapeutic cancer vaccines. Cancer J (Sudbury Mass). 2011;17(5):359.
doi: 10.1097/PPO.0b013e3182325e63
Patel SP, Petroni GR, Roszik J, Olson WC, Wages NA, Chianese-Bullock KA et al. Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma. J Immunother Cancer. 2021;9(8).
Yuan J, Ku GY, Adamow M, Mu Z, Tandon S, Hannaman D, et al. Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. J Immunother Cancer. 2013;1:1–11.
doi: 10.1186/2051-1426-1-20
Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, et al. mRNA-based cancer vaccines: a therapeutic strategy for the treatment of melanoma patients. Vaccines. 2021;9(10):1060.
pubmed: 34696168
doi: 10.3390/vaccines9101060
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discovery. 2018;17(4):261–79.
pubmed: 29326426
doi: 10.1038/nrd.2017.243
Lee S, Margolin K. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep. 2012;14:468–74.
pubmed: 22878966
doi: 10.1007/s11912-012-0257-5
Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656.
pubmed: 33979178
doi: 10.1200/JCO.21.00612
Haanen J, Rohaan M, Borch T, Van den Berg J, Met Ö, Foppen MG, et al. LBA3 treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: results from a multicenter, randomized phase III trial. Ann Oncol. 2022;33:S1406.
doi: 10.1016/j.annonc.2022.08.036
Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, et al. Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. Front Oncol. 2018;8:44.
pubmed: 29552542
doi: 10.3389/fonc.2018.00044
Geukes Foppen MH, Donia M, Borch TH, Met Ö, Blank CU, Pronk L, et al. Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma. American Society of Clinical Oncology; 2016.
Balch CM, Gershenwald JE, Soong S-j, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199.
pubmed: 19917835
doi: 10.1200/JCO.2009.23.4799
Tarhini AA. The current state of adjuvant therapy of melanoma. Lancet Oncol. 2020;21(11):1394–5.
pubmed: 32961120
doi: 10.1016/S1470-2045(20)30544-1
Testori AA, Chiellino S, van Akkooi AC. Adjuvant therapy for melanoma: past, current, and future developments. Cancers. 2020;12(7):1994.
pubmed: 32708268
doi: 10.3390/cancers12071994
Mocellin S, Lens MB, Pasquali S, Pilati P, Sileni VC. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Reviews. 2013(6).
Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493–501.
pubmed: 20179267
doi: 10.1093/jnci/djq009
Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5):1670–7.
pubmed: 15014018
doi: 10.1158/1078-0432.CCR-1103-3
Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–58.
pubmed: 10856105
doi: 10.1200/JCO.2000.18.12.2444
Eggermont A, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810–8.
pubmed: 23008300
doi: 10.1200/JCO.2011.41.3799
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.
pubmed: 28891423
doi: 10.1056/NEJMoa1709030
Larkin J, Del Vecchio M, Mandalá M, Gogas H, Arance Fernandez AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023;29(17):3352–61.
pubmed: 37058595
doi: 10.1158/1078-0432.CCR-22-3145
Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643–54.
pubmed: 33857412
doi: 10.1016/S1470-2045(21)00065-6
Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, et al. Adjuvant pembrolizumab versus IFNα2b or ipilimumab in resected high-risk melanoma. Cancer Discov. 2022;12(3):644–53.
pubmed: 34764195
doi: 10.1158/2159-8290.CD-21-1141
Qin Z, Zheng M. Advances in targeted therapy and immunotherapy for melanoma. Experimental Therapeutic Med. 2023;26(3):1–23.
doi: 10.3892/etm.2023.12115
Russell SJ, Peng K-W. Viruses as anticancer drugs. Trends Pharmacol Sci. 2007;28(7):326–33.
pubmed: 17573126
pmcid: 3125087
doi: 10.1016/j.tips.2007.05.005
Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658.
pubmed: 28981385
doi: 10.1200/JCO.2017.73.7379
Nahand JS, Vandchali NR, Darabi H, Doroudian M, Banafshe HR, Moghoofei M, et al. Exosomal microRNAs: novel players in cervical cancer. Epigenomics. 2020;12(18):1651–60.
pubmed: 32957811
doi: 10.2217/epi-2020-0026
Xiong M, Zhang Q, Hu W, Zhao C, Lv W, Yi Y, et al. The novel mechanisms and applications of exosomes in dermatology and cutaneous medical aesthetics. Pharmacol Res. 2021;166:105490.
pubmed: 33582246
doi: 10.1016/j.phrs.2021.105490
Rahimian S, Najafi H, Afzali B, Doroudian M. Extracellular vesicles and exosomes: novel insights and perspectives on lung cancer from early detection to targeted treatment. Biomedicines. 2024;12(1):123.
pubmed: 38255228
pmcid: 10813125
doi: 10.3390/biomedicines12010123
Czystowska-Kuzmicz M, Whiteside TL. The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer. Expert Opin Biol Ther. 2021;21(2):241–58.
pubmed: 32813990
doi: 10.1080/14712598.2020.1813276
Azhdari MH, Goodarzi N, Doroudian M, MacLoughlin R. Molecular insight into the therapeutic effects of stem cell-derived exosomes in respiratory diseases and the potential for pulmonary delivery. Int J Mol Sci. 2022;23(11):6273.
pubmed: 35682948
pmcid: 9181737
doi: 10.3390/ijms23116273
Arasi MB, Pedini F, Valentini S, Felli N, Felicetti F. Advances in natural or synthetic nanoparticles for metastatic melanoma therapy and diagnosis. Cancers. 2020;12(10):2893.
pubmed: 33050185
pmcid: 7601614
doi: 10.3390/cancers12102893
Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56.
pubmed: 31578484
doi: 10.1038/s41586-019-1593-5
Lyu C, Sun H, Sun Z, Liu Y, Wang Q. Roles of exosomes in immunotherapy for solid cancers. Cell Death Dis. 2024;15(2):106.
pubmed: 38302430
pmcid: 10834551
doi: 10.1038/s41419-024-06494-z
Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discovery. 2022;21(7):529–40.
pubmed: 35701637
doi: 10.1038/s41573-022-00493-5
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94.
pubmed: 25667295
doi: 10.1200/JCO.2014.56.2736
Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–8.
pubmed: 30715153
doi: 10.1093/annonc/mdz011
Kalluri R. The biology and function of exosomes in cancer. J Clin Investig. 2016;126(4):1208–15.
pubmed: 27035812
doi: 10.1172/JCI81135
Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med. 2013;91:431–7.
pubmed: 23519402
doi: 10.1007/s00109-013-1020-6
Choi S-J, Cho H, Yea K, Baek M-C. Immune cell-derived small extracellular vesicles in cancer treatment. BMB Rep. 2022;55(1):48.
pubmed: 34353429
doi: 10.5483/BMBRep.2022.55.1.133
Sen S, Xavier J, Kumar N, Ahmad MZ, Ranjan OP. Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. 3 Biotech. 2023;13(3):101.
pubmed: 36860361
doi: 10.1007/s13205-023-03521-2
Kim H, Jang H, Cho H, Choi J, Hwang KY, Choi Y, et al. Recent advances in exosome-based drug delivery for cancer therapy. Cancers. 2021;13(17):4435.
pubmed: 34503245
doi: 10.3390/cancers13174435
Ghasempour E, Hesami S, Movahed E, Keshel SH, Doroudian M. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors. Stem Cell Res Ther. 2022;13(1):527.
pubmed: 36536420
doi: 10.1186/s13287-022-03212-4
Heydari R, Koohi F, Rasouli M, Rezaei K, Abbasgholinejad E, Bekeschus S, et al. Exosomes as rheumatoid arthritis diagnostic biomarkers and therapeutic agents. Vaccines. 2023;11(3):687.
pubmed: 36992270
doi: 10.3390/vaccines11030687
Moosavian SA, Hashemi M, Etemad L, Daneshmand S, Salmasi Z. Melanoma-derived exosomes: versatile extracellular vesicles for diagnosis, metastasis, immune modulation, and treatment of melanoma. Int Immunopharmacol. 2022;113:109320.
doi: 10.1016/j.intimp.2022.109320
Syn NL, Wang L, Chow EK-H, Lim CT, Goh B-C. Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges. Trends Biotechnol. 2017;35(7):665–76.
pubmed: 28365132
doi: 10.1016/j.tibtech.2017.03.004
Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sinica B. 2016;6(4):287–96.
doi: 10.1016/j.apsb.2016.02.001
Akuma P, Okagu OD, Udenigwe CC. Naturally occurring exosome vesicles as potential delivery vehicle for bioactive compounds. Front Sustainable Food Syst. 2019;3:23.
doi: 10.3389/fsufs.2019.00023
Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183.
pubmed: 33537081
doi: 10.7150/thno.52570
Yang P, Peng Y, Feng Y, Xu Z, Feng P, Cao J, et al. Immune cell-derived extracellular vesicles–new strategies in cancer immunotherapy. Front Immunol. 2021;12:771551.
pubmed: 34956197
doi: 10.3389/fimmu.2021.771551
Enomoto Y, Li P, Jenkins LM, Anastasakis D, Lyons GC, Hafner M, et al. Cytokine-enhanced cytolytic activity of exosomes from NK cells. Cancer Gene Ther. 2022;29(6):734–49.
pubmed: 34316033
doi: 10.1038/s41417-021-00352-2
Cho H, Jung I, Ju H, Baek M-C, Yea K. Engineered CD8 + T cell-derived extracellular vesicles induce enhanced anti-cancer efficacy and targeting to lung cancer cells. Cytokine. 2023;169:156249.
pubmed: 37290276
doi: 10.1016/j.cyto.2023.156249
Jung I, Shin S, Baek M-C, Yea K. Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications. Exp Mol Med. 2024;56(1):19–31.
pubmed: 38172594
doi: 10.1038/s12276-023-01132-8
Liu C, Liu X, Xiang X, Pang X, Chen S, Zhang Y, et al. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat Nanotechnol. 2022;17(5):531–40.
pubmed: 35410368
doi: 10.1038/s41565-022-01098-0
Zhou Q, Yan Y, Li Y, Fu H, Lu D, Li Z, et al. Tumor-derived extracellular vesicles in melanoma immune response and immunotherapy. Biomed Pharmacother. 2022;156:113790.
pubmed: 36244269
doi: 10.1016/j.biopha.2022.113790
Hanjani NA, Esmaelizad N, Zanganeh S, Gharavi AT, Heidarizadeh P, Radfar M, et al. Emerging role of exosomes as biomarkers in cancer treatment and diagnosis. Crit Rev Oncol/Hematol. 2022;169:103565.
pubmed: 34871719
doi: 10.1016/j.critrevonc.2021.103565
Zhang H, Wang S, Sun M, Cui Y, Xing J, Teng L, et al. Exosomes as smart drug delivery vehicles for cancer immunotherapy. Front Immunol. 2023;13:1093607.
pubmed: 36733388
doi: 10.3389/fimmu.2022.1093607
Didiot M-C, Hall LM, Coles AH, Haraszti RA, Godinho BM, Chase K, et al. Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing. Mol Ther. 2016;24(10):1836–47.
pubmed: 27506293
doi: 10.1038/mt.2016.126
Wang D, Wan Z, Yang Q, Chen J, Liu Y, Lu F, et al. Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes. Drug Delivery. 2022;29(1):702–13.
pubmed: 35236203
doi: 10.1080/10717544.2022.2044937
Xi X-M, Xia S-J, Lu R. Drug loading techniques for exosome-based drug delivery systems. Die Pharmazie-An Int J Pharm Sci. 2021;76(2–3):61–7.
Familtseva A, Jeremic N, Tyagi SC, Exosomes. Cell-created drug delivery systems. Mol Cell Biochem. 2019;459:1–6.
pubmed: 31073888
doi: 10.1007/s11010-019-03545-4
Pomatto MAC, Bussolati B, D’Antico S, Ghiotto S, Tetta C, Brizzi MF, et al. Improved loading of plasma-derived extracellular vesicles to encapsulate antitumor miRNAs. Mol Therapy-Methods Clin Dev. 2019;13:133–44.
doi: 10.1016/j.omtm.2019.01.001
Liao W, Du Y, Zhang C, Pan F, Yao Y, Zhang T, et al. Exosomes: the next generation of endogenous nanomaterials for advanced drug delivery and therapy. Acta Biomater. 2019;86:1–14.
pubmed: 30597259
doi: 10.1016/j.actbio.2018.12.045
Salarpour S, Forootanfar H, Pournamdari M, Ahmadi-Zeidabadi M, Esmaeeli M, Pardakhty A. Paclitaxel incorporated exosomes derived from glioblastoma cells: comparative study of two loading techniques. DARU J Pharm Sci. 2019;27:533–9.
doi: 10.1007/s40199-019-00280-5
Yang Z, Xie J, Zhu J, Kang C, Chiang C, Wang X, et al. Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation. J Controlled Release. 2016;243:160–71.
doi: 10.1016/j.jconrel.2016.10.008
Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26(35):5748.
pubmed: 19001327
pmcid: 2645104
doi: 10.1200/JCO.2008.17.5448
Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schiffelers RM, Andaloussi SE et al. Extracellular vesicles as drug delivery systems: why and how? Advanced drug delivery reviews. 2020;159:332–43.
Patras L, Ionescu AE, Munteanu C, Hajdu R, Kosa A, Porfire A, et al. Trojan horse treatment based on PEG-coated extracellular vesicles to deliver doxorubicin to melanoma in vitro and in vivo. Cancer Biol Ther. 2022;23(1):1–16.
pubmed: 34964693
doi: 10.1080/15384047.2021.2003656
Zhao Y, Gu Y, Qi F, Li A, Tang X, Li D, et al. Engineering adipocytes for targeting delivery of triptolide derivative and Ce6 for malignant melanoma cytotoxic-PDT synergistic strategy. Mater Design. 2023;228:111860.
doi: 10.1016/j.matdes.2023.111860
Jiang L, Gu Y, Du Y, Tang X, Wu X, Liu J. Engineering exosomes endowed with targeted delivery of triptolide for malignant melanoma therapy. ACS Appl Mater Interfaces. 2021;13(36):42411–28.
pubmed: 34464081
doi: 10.1021/acsami.1c10325
Wang N, Liu C, Li Y, Huang D, Wu X, Kou X, et al. A cooperative nano-CRISPR scaffold potentiates immunotherapy via activation of tumour-intrinsic pyroptosis. Nat Commun. 2023;14(1):779.
pubmed: 36774382
pmcid: 9922300
doi: 10.1038/s41467-023-36550-9
Wang X, Liu Y, Xue C, Hu Y, Zhao Y, Cai K, et al. A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses. Nat Commun. 2022;13(1):5685.
pubmed: 36167857
doi: 10.1038/s41467-022-33301-0
Li P, Xie Y, Wang J, Bao C, Duan J, Liu Y, et al. Gene engineered exosome reverses T cell exhaustion in cancer immunotherapy. Bioactive Mater. 2024;34:466–81.
doi: 10.1016/j.bioactmat.2024.01.008
Chen Y-F, Luh F, Ho Y-S, Yen Y. Exosomes: a review of biologic function, diagnostic and targeted therapy applications, and clinical trials. J Biomed Sci. 2024;31(1):67.
pubmed: 38992695
doi: 10.1186/s12929-024-01055-0
Grolmusz VK, Karászi K, Micsik T, Tóth EA, Mészáros K, Karvaly G, et al. Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. Am J cancer Res. 2016;6(9):2041.
pubmed: 27725909
Zheng Z, Li Z, Xu C, Guo B, Guo P. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J Controlled Release. 2019;311:43–9.
doi: 10.1016/j.jconrel.2019.08.021
Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, et al. Cancer vaccines: the next immunotherapy frontier. Nat cancer. 2022;3(8):911–26.
pubmed: 35999309
doi: 10.1038/s43018-022-00418-6
Saxena M, van der Burg SH, Melief CJ, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360–78.
pubmed: 33907315
doi: 10.1038/s41568-021-00346-0
Luo S, Chen J, Xu F, Chen H, Li Y, Li W. Dendritic cell-derived exosomes in cancer immunotherapy. Pharmaceutics. 2023;15(8):2070.
pubmed: 37631284
doi: 10.3390/pharmaceutics15082070
Xie J, Zheng Z, Tuo L, Deng X, Tang H, Peng C, et al. Recent advances in exosome-based immunotherapy applied to cancer. Front Immunol. 2023;14:1296857.
pubmed: 38022585
doi: 10.3389/fimmu.2023.1296857
Hao S, Liu Y, Yuan J, Zhang X, He T, Wu X, et al. Novel exosome-targeted CD4 + T cell vaccine counteracting CD4 + 25 + regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8 + CTL responses. J Immunol. 2007;179(5):2731–40.
pubmed: 17709486
doi: 10.4049/jimmunol.179.5.2731
Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298–312.
pubmed: 33750922
doi: 10.1038/s41568-021-00339-z
Escudier B, Dorval T, Chaput N, André F, Caby M-P, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Translational Med. 2005;3:1–13.
doi: 10.1186/1479-5876-3-10
Damo M, Wilson DS, Simeoni E, Hubbell JA. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. Sci Rep. 2015;5(1):17622.
pubmed: 26631690
doi: 10.1038/srep17622
Gehrmann U, Hiltbrunner S, Georgoudaki A-M, Karlsson MC, Näslund TI, Gabrielsson S. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. Cancer Res. 2013;73(13):3865–76.
pubmed: 23658368
doi: 10.1158/0008-5472.CAN-12-3918
Kibria G, Ramos EK, Wan Y, Gius DR, Liu H. Exosomes as a drug delivery system in cancer therapy: potential and challenges. Mol Pharm. 2018;15(9):3625–33.
pubmed: 29771531
doi: 10.1021/acs.molpharmaceut.8b00277
Naseri M, Bozorgmehr M, Zöller M, Ranaei Pirmardan E, Madjd Z. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy. Oncoimmunology. 2020;9(1):1779991.
pubmed: 32934883
doi: 10.1080/2162402X.2020.1779991
Dai Z, Cai R, Zeng H, Zhu H, Dou Y, Sun S. Exosome may be the next generation of promising cell-free vaccines. Hum Vaccines Immunotherapeutics. 2024;20(1):2345940.
doi: 10.1080/21645515.2024.2345940
Li Q, Cai S, Li M, Salma KI, Zhou X, Han F et al. Tumor-derived extracellular vesicles: their role in immune cells and immunotherapy. Int J Nanomed. 2021:5395–409.
Wang L, Sun Z, Wang H. Extracellular vesicles and the regulation of tumor immunity: current progress and future directions. J Cell Biochem. 2021;122(7):760–9.
pubmed: 33594754
doi: 10.1002/jcb.29904
Lee E-Y, Park K-S, Yoon YJ, Lee J, Moon H-G, Jang SC, et al. Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis. PLoS ONE. 2012;7(3):e33330.
pubmed: 22438914
doi: 10.1371/journal.pone.0033330
Park KS, Svennerholm K, Crescitelli R, Lässer C, Gribonika I, Lötvall J. Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy. J Extracell Vesicles. 2021;10(9):e12120.
pubmed: 34262675
doi: 10.1002/jev2.12120
Lv F, Liu H, Zhao G, Zhao E, Yan H, Che R et al. Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment. Iscience. 2022;25(1).
Shin S, Jung I, Jung D, Kim CS, Kang S-M, Ryu S, et al. Novel antitumor therapeutic strategy using CD4 + T cell-derived extracellular vesicles. Biomaterials. 2022;289:121765.
pubmed: 36067566
doi: 10.1016/j.biomaterials.2022.121765
Lu J, Wu J, Xie F, Tian J, Tang X, Guo H, et al. CD4 + T cell-released extracellular vesicles potentiate the efficacy of the HBsAg vaccine by enhancing B cell responses. Adv Sci. 2019;6(23):1802219.
doi: 10.1002/advs.201802219
Wu S-W, Li L, Wang Y, Xiao Z. CTL-derived exosomes enhance the activation of CTLs stimulated by low-affinity peptides. Front Immunol. 2019;10:1274.
pubmed: 31275303
doi: 10.3389/fimmu.2019.01274
Jung D, Shin S, Kang SM, Jung I, Ryu S, Noh S, et al. Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti‐cancer effects through miRNA delivery. J Extracell Vesicles. 2022;11(12):12287.
pubmed: 36447429
pmcid: 9709340
doi: 10.1002/jev2.12287
Balsamo M, Pietra G, Vermi W, Moretta L, Mingari MC, Vitale M. Melanoma immunoediting by NK cells. Oncoimmunology. 2012;1(9):1607–9.
pubmed: 23264909
pmcid: 3525618
doi: 10.4161/onci.21456
Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell functions. Cancer Res. 2012;72(20):5428–9.
pubmed: 23047870
doi: 10.1158/0008-5472.CAN-12-1181
Kang YT, Niu Z, Hadlock T, Purcell E, Lo TW, Zeinali M, et al. On-chip biogenesis of circulating NK cell‐derived exosomes in non‐small cell lung cancer exhibits antitumoral activity. Adv Sci. 2021;8(6):2003747.
doi: 10.1002/advs.202003747
Jong AY, Wu C-H, Li J, Sun J, Fabbri M, Wayne AS, et al. Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles. 2017;6(1):1294368.
pubmed: 28326171
doi: 10.1080/20013078.2017.1294368
Zhu L, Kalimuthu S, Gangadaran P, Oh JM, Lee HW, Baek SH, et al. Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics. 2017;7(10):2732.
pubmed: 28819459
pmcid: 5558565
doi: 10.7150/thno.18752
Fais S. NK cell-released exosomes: natural nanobullets against tumors. Oncoimmunology. 2013;2(1):e22337.
pubmed: 23482694
doi: 10.4161/onci.22337
Lugini L, Cecchetti S, Huber V, Luciani F, Macchia G, Spadaro F, et al. Immune surveillance properties of human NK cell-derived exosomes. J Immunol. 2012;189(6):2833–42.
pubmed: 22904309
doi: 10.4049/jimmunol.1101988
Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci. 2008;105(45):17481–6.
pubmed: 18987320
doi: 10.1073/pnas.0804788105
Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol. 2013;4:490.
pubmed: 24400010
doi: 10.3389/fimmu.2013.00490
Ames E, Hallett W, Murphy W. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Experimental Immunol. 2009;155(3):504–13.
doi: 10.1111/j.1365-2249.2008.03818.x
Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284(49):34211–22.
pubmed: 19801663
doi: 10.1074/jbc.M109.041152
Meng W, Hao Y, He C, Li L, Zhu G. Exosome-orchestrated hypoxic tumor microenvironment. Mol Cancer. 2019;18:1–14.
doi: 10.1186/s12943-019-0982-6
Gharavi AT, Hanjani NA, Movahed E, Doroudian M. The role of macrophage subtypes and exosomes in immunomodulation. Cell Mol Biol Lett. 2022;27(1):83.
pubmed: 36192691
doi: 10.1186/s11658-022-00384-y
Choo YW, Kang M, Kim HY, Han J, Kang S, Lee J-R, et al. M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors. ACS Nano. 2018;12(9):8977–93.
pubmed: 30133260
doi: 10.1021/acsnano.8b02446
Gunassekaran GR, Vadevoo SMP, Baek M-C, Lee B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021;278:121137.
pubmed: 34560422
doi: 10.1016/j.biomaterials.2021.121137
Wang S, Li F, Ye T, Wang J, Lyu C, Qing S, et al. Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. Sci Transl Med. 2021;13(615):eabb6981.
pubmed: 34644149
doi: 10.1126/scitranslmed.abb6981
Padda J, Khalid K, Khedr A, Patel V, Al-Ewaidat OA, Tasnim F, et al. Exosome-derived microRNA: efficacy in cancer. Cureus. 2021;13:8.
Li J, Chen J, Wang S, Li P, Zheng C, Zhou X, et al. Blockage of transferred exosome-shuttled miR‐494 inhibits melanoma growth and metastasis. J Cell Physiol. 2019;234(9):15763–74.
pubmed: 30723916
doi: 10.1002/jcp.28234
Ye J, Li D, Jie Y, Luo H, Zhang W, Qiu C. Exosome-based nanoparticles and cancer immunotherapy. Biomed Pharmacother. 2024;179:117296.
pubmed: 39167842
doi: 10.1016/j.biopha.2024.117296
Ye H, Wang K, Zhao J, Lu Q, Wang M, Sun B, et al. In situ sprayed nanovaccine suppressing exosomal PD-L1 by golgi apparatus disorganization for postsurgical melanoma immunotherapy. ACS Nano. 2023;17(11):10637–50.
pubmed: 37213184
doi: 10.1021/acsnano.3c01733
Wang G, Xie L, Li B, Sang W, Yan J, Li J, et al. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis. Nat Commun. 2021;12(1):5733.
pubmed: 34593794
doi: 10.1038/s41467-021-25990-w
Yang Q, Li S, Ou H, Zhang Y, Zhu G, Li S, et al. Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application. J Nanobiotechnol. 2024;22(1):41.
doi: 10.1186/s12951-024-02298-7
Wang J, Chen D, Ho EA. Challenges in the development and establishment of exosome-based drug delivery systems. J Controlled Release. 2021;329:894–906.
doi: 10.1016/j.jconrel.2020.10.020
Ahn S-H, Ryu S-W, Choi H, You S, Park J, Choi C. Manufacturing therapeutic exosomes: from bench to industry. Mol Cells. 2022;45(5):284–90.
pubmed: 35534190
doi: 10.14348/molcells.2022.2033
Tacheny A. Scaling-up the production of stem cell-derived extracellular vesicles in stirred-tank bioreactors. Cell and Gene Therapy Insights; 2021.
Yamashita T, Takahashi Y, Takakura Y. Possibility of exosome-based therapeutics and challenges in production of exosomes eligible for therapeutic application. Biol Pharm Bull. 2018;41(6):835–42.
pubmed: 29863072
doi: 10.1248/bpb.b18-00133
Kong L, Yang C, Zhang Z. Organism-generated Biological vesicles in situ: an Emerging Drug Delivery Strategy. Adv Sci. 2023;10(2):2204178.
doi: 10.1002/advs.202204178
Sanghani A, Andriesei P, Kafetzis KN, Tagalakis AD, Yu-Wai‐Man C. Advances in exosome therapies in ophthalmology–from bench to clinical trial. Acta Ophthalmol. 2022;100(3):243–52.
pubmed: 34114746
doi: 10.1111/aos.14932
Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35(4):851–8.
pubmed: 28294454
doi: 10.1002/stem.2575
Chen L-Y, Kao T-W, Chen C-C, Niaz N, Lee H-L, Chen Y-H, et al. Frontier review of the molecular mechanisms and current approaches of stem cell-derived exosomes. Cells. 2023;12(7):1018.
pubmed: 37048091
doi: 10.3390/cells12071018
Negrea G, Rauca V-F, Meszaros MS, Patras L, Luput L, Licarete E, et al. Active tumor-targeting nano-formulations containing simvastatin and doxorubicin inhibit melanoma growth and angiogenesis. Front Pharmacol. 2022;13:870347.
pubmed: 35450036
doi: 10.3389/fphar.2022.870347
Kang C, Han P, Lee JS, Lee D, Kim D. Anchor, spacer, and ligand-modified engineered exosomes for trackable targeted therapy. Bioconjug Chem. 2020;31(11):2541–52.
pubmed: 33115231
doi: 10.1021/acs.bioconjchem.0c00483
Gu Y, Du Y, Jiang L, Tang X, Li A, Zhao Y, et al. αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma. J Nanobiotechnol. 2022;20(1):384.
doi: 10.1186/s12951-022-01597-1
Iessi E, Logozzi M, Lugini L, Azzarito T, Federici C, Spugnini EP, et al. Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: a new prototype for theranostics of tumors. J Enzyme Inhib Med Chem. 2017;32(1):648–57.
pubmed: 28262028
doi: 10.1080/14756366.2017.1292263
Chen H, Jiang Y, Li X. Adriamycin-loaded exosome with anti‐CD20 aptamers selectively suppresses human CD20 + melanoma stem cells. Skin Res Technol. 2023;29(1):e13259.
pubmed: 36704890
doi: 10.1111/srt.13259
Fan Y, Zhou Y, Lu M, Si H, Li L, Tang B. Responsive dual-targeting exosome as a drug carrier for combination cancer immunotherapy. Research. 2021.
Lin J, Huang N, Li M, Zheng M, Wang Z, Zhang X, et al. Dendritic cell-derived exosomes driven drug co-delivery biomimetic nanosystem for effective combination of malignant melanoma immunotherapy and gene therapy. Development and Therapy: Drug Design; 2023. pp. 2087–106.
Zhu H, Zhang P, Shi J, Kou D, Bai X. Exosome-delivered circRPS5 inhibits the progression of melanoma via regulating the miR-151a/NPTX1 axis. PLoS ONE. 2023;18(6):e0287347.
pubmed: 37384727
doi: 10.1371/journal.pone.0287347
Li J, Li J, Peng Y, Du Y, Yang Z, Qi X. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. J Controlled Release. 2023;353:423–33.
doi: 10.1016/j.jconrel.2022.11.053
Jung M, Kang M, Kim BS, Hong J, Kim C, Koh CH, et al. Nanovesicle-mediated targeted delivery of immune checkpoint blockades to potentiate therapeutic efficacy and prevent side effects. Adv Mater. 2022;34(9):2106516.
doi: 10.1002/adma.202106516
Fan M, Liu H, Yan H, Che R, Jin Y, Yang X, et al. A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy. Biomaterials. 2022;282:121424.
pubmed: 35196606
doi: 10.1016/j.biomaterials.2022.121424
Lee YS, Kim SH, Cho JA, Kim CW. Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects. Exp Mol Med. 2011;43(5):281–90.
pubmed: 21464590
doi: 10.3858/emm.2011.43.5.029
Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y. Exosome-based tumor antigens–adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials. 2016;111:55–65.
pubmed: 27723556
doi: 10.1016/j.biomaterials.2016.09.031
Koyama Y, Ito T, Hasegawa A, Eriguchi M, Inaba T, Ushigusa T, et al. Exosomes derived from tumor cells genetically modified to express Mycobacterium tuberculosis antigen: a novel vaccine for cancer therapy. Biotechnol Lett. 2016;38:1857–66.
pubmed: 27484689
doi: 10.1007/s10529-016-2185-1
Cho J-a, Lee Y-S, Kim S-H, Ko J-K, Kim C-W. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. Cancer Lett. 2009;275(2):256–65.
pubmed: 19036499
doi: 10.1016/j.canlet.2008.10.021
Temchura VV, Tenbusch M, Nchinda G, Nabi G, Tippler B, Zelenyuk M, et al. Enhancement of immunostimulatory properties of exosomal vaccines by incorporation of fusion-competent G protein of vesicular stomatitis virus. Vaccine. 2008;26(29–30):3662–72.
pubmed: 18538453
doi: 10.1016/j.vaccine.2008.04.069
Hu S, Ma J, Su C, Chen Y, Shu Y, Qi Z, et al. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater. 2021;135:567–81.
pubmed: 34506976
doi: 10.1016/j.actbio.2021.09.003
Naeem P, Baumgartner A, Ghaderi N, Sefat F, Alhawamdeh M, Heidari S, et al. Anticarcinogenic impact of extracellular vesicles (exosomes) from cord blood stem cells in malignant melanoma: a potential biological treatment. J Cell Mol Med. 2023;27(2):222–31.
pubmed: 36545841
doi: 10.1111/jcmm.17639
Bae I-S, Kim SH. Milk exosome-derived MicroRNA-2478 suppresses melanogenesis through the akt-gsk3β pathway. Cells. 2021;10(11):2848.
pubmed: 34831071
doi: 10.3390/cells10112848
Shamili FH, Bayegi HR, Salmasi Z, Sadri K, Mahmoudi M, Kalantari M, et al. Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model. Int J Pharm. 2018;549(1–2):218–29.
pubmed: 30075248
doi: 10.1016/j.ijpharm.2018.07.067